by Aras Rezvanian | Nov 30, 2018 | Niemann-Pick Type A |
Niemann-Pick Type A (NPA) affects about 1 in 250,000 individuals, with a higher frequency in individuals of Ashkenazi Jewish descent, where it’s about 1 in 40,000. NPA is caused by a mutation in the SMPD1 gene, a gene encoding acid sphingomyelinase which, when...
by Sangeetha Iyer | Feb 6, 2018 | Niemann-Pick Type A |
In December of 2016, Perlara partnered with Wylder Nation to initiate an NPA PerlQuest, a research and drug discovery program for Niemann Pick Type A disease. If you’ve been following our blog, you’ve kept up with our fly team’s efforts in...
by Joshua Mast | Jan 22, 2018 | Niemann-Pick Type A |
A few months ago, Taryn Sumabat blogged about development of a fly model of a Niemann-Pick Type A Disease. Here I’ll remind you of the progress she described, and update you on our more recent work. If you remember, the two main objectives for this phase of our NPA...
by Ethan Perlstein | Sep 21, 2017 | Niemann-Pick Type A |
By Taryn Sumabat This summer at Perlara, we ramped up our efforts to develop a Drosophila model of Niemann-Pick Type A (NPA). NPA is a rare lysosomal storage disease caused by mutations in the gene Smpd1, which encodes an enzyme called acid sphingomyelinase (ASM)....
